BALB/c mice were immunized against the 19 Cterminal amino acids of the mouse mammary tumour virus [MMTV(SW)] superantigen, either actively with the recombinant ORF19 protein or passively by subcutaneous implantation of 6E1.8 hybridoma cells. Protection against the MMTV(SW) superantigen-induced activation of specific T cells was obtained in both immunizations. Whereas the monoclonal antibody provided complete protection, similar antibody titres showed less effective protection in actively immunized mice. This was due to the presence of a histidine tag on the recombinant ORF19 protein preventing immune recognition of the C-terminal amino acids during immunization. Preincubation of the 6E1.8 monoclonal antibodies with modified ORF19 peptides at their C terminus established specific recognition of the last two amino acids of MMTV(SW) superantigen by this antibody, and showed that these amino acids are critical in the interaction between the MMTV(SW) superantigen and the Vβ element of the T-cell receptor.
BALB/c mice were immunized against the 19 Cterminal amino acids of the mouse mammary tumour virus [MMTV(SW)] superantigen, either actively with the recombinant ORF19 protein or passively by subcutaneous implantation of 6E1.8 hybridoma cells. Protection against the MMTV(SW) superantigen-induced activation of specific T cells was obtained in both immunizations. Whereas the monoclonal antibody provided complete protection, similar antibody titres showed less effective protection in actively immunized mice. This was due to the presence of a histidine tag on the recombinant ORF19 protein preventing immune recognition of the C-terminal amino acids during immunization. Preincubation of the 6E1.8 monoclonal antibodies with modified ORF19 peptides at their C terminus established specific recognition of the last two amino acids of MMTV(SW) superantigen by this antibody, and showed that these amino acids are critical in the interaction between the MMTV(SW) superantigen and the Vβ element of the T-cell receptor.
Mouse mammary tumour virus (MMTV) has evolved to ensure optimal transmission from generation to generation, which occurs in newborn mice through infection of Peyer's patches. This lymphoid organ is the first to be sufficiently mature for support of virus replication and spread in the organism (Karapetian et al., 1994) . After infecting B cells MMTV expresses a superantigen (SAg) (Choi et al., 1991 ; Marrack et al., 1991 ; Acha Orbea et al., 1991) Fax j41 21 314 08 01. e-mail mastori!eliot.unil.ch activation of specific CD4 + T cells, which in turn stimulate the proliferation of infected B cells and their subsequent spread through the organism (for recent reviews see Huber et al., 1996 ; Luther & Acha Orbea, 1996) .
As early as 5 days after infection, systemic injection of MMTV(SW) into BALB\c mice triggers a strong increase of the SAg-responding Vβ6 + CD4 + T cells from 12 to 35 % . The specificity of this Vβ6 activation depends on the last 19 amino acids at the C terminus of the SAg, which are encoded by a polymorphic sequence in the U3 region of the ORF from the 3h long terminal repeat . These amino-acid residues therefore play a crucial role in the virusinduced immune response.
In order to protect mice early from retroviral infection, systemic vaccinations must be aimed at two sequentially distinct stages : firstly at the virus-cell membrane interaction, where immunization against the major viral envelope protein gp52 can prevent the entry of MMTV into B cells (Astori & Karapetian, 1997) , and secondly at the interaction between the MHC class II-MMTV SAg complex and the Vβ element on the TCR. Vaccination against the C-terminal amino acids of the MMTV(SW) SAg would be expected to produce that necessary protection. The proliferation of infected B cells and subsequent virus replication might be inhibited through neutralization of the T-cell-dependent cognate help to the infected B cells. The passive transfer of a monoclonal antibody (MAb) against the MMTV(SW) SAg and the parallel infection of mice by MMTV(SW) has already been shown to diminish the intensity of the specific T-cell proliferation (Acha . However, no active anti-SAg vaccination study has yet been reported.
Anti-gp52 immunization has been shown to provide incomplete protection. The reasons for this have been discussed previously (Astori & Karapetian, 1997) . We therefore became interested in exploring the use of anti-SAg vaccination as a way of preventing the interaction of the TCR with SAg expressed by those viral particles which escape neutralization.
In this study, we have used both active and passive immunization to determine the effectiveness of anti-SAg vaccination in inhibiting MMTV-induced T-cell-specific activation, and have analysed the immunodominant role played (Astori & Kraehenbuhl, 1996) . Groups of mice with varying titres of anti-ORF19 antibodies were selected by ELISA and infected by footpad injection of MMTV(SW). The percentage of Vβ6 + CD4 + T cells was determined by fluorescence-activated cell sorting (FACS) analysis at day 5 after infection in the draining popliteal lymph node. Horizontal lines represent the arithmetic mean with the standard deviation of the percentage of Vβ6 + CD4 + T cells in immunized but non-infected BALB/c control mice. Vertical lines represent the standard deviation of the arithmetic mean of two to five mice. ND, Not detectable. Infectious MMTV(SW) was obtained from BALB/c mice (IFFA Credo, L'Arbresle, France) and titrated as described by Held et al. (1992) . About 2i10 6 to 2i10 7 viral particles were injected per mouse. The same batch of MMTV(SW) was used for all experiments.
by the C-terminal dipeptide sequence of MMTV(SW) SAg in the immune response induced by the retroviral infection.
We began with the assumption that high titres of anti-SAg antibodies would be necessary to inhibit the very potent phenomenon of activation of T cells triggered by the MMTV(SW) SAg. Therefore BALB\c mice were first immunized with a recombinant protein associating the P30 Thelper epitope from the tetanus toxin with the 19 C-terminal amino acids of the MMTV(SW) SAg, ORF19. In order to facilitate its purification, this recombinant protein was linked by its C terminus to a histidine tag. Such a vaccination strategy has been shown to produce very high titres of anti-epitopic antibodies (Astori & Kraehenbuhl, 1996) . The immunized mice were then separated into different groups by the titres of their specific antibodies against the ORF19 epitope, ranging from 1 : 200 to 1 : 819 200. They were then infected in the footpad with MMTV(SW) particles. Results from vaccination with this active recombinant protein showed that mice with titres exceeding 1 : 102 400 were protected significantly against Tcell activation (Fig. 1) . Complete inhibition, however, could not be obtained.
An MAb called 6E1.8 has been produced using the 19 Cterminal amino acids of MMTV(SW) SAg as an immunogen. The clone secreting the antibody was selected in vitro by mixed lymphocyte reaction assay for its optimal capacity to inhibit lymphocyte activation. This antibody is known to reduce specific T-cell activation in vivo when injected in parallel with the MMTV(SW) (Acha . We sought to determine the titre of this MAb which could protect mice in vivo from MMTV(SW)-induced T-cell activation. To this end we developed an immunization strategy whereby adult mice were injected subcutaneously with varying numbers of the 6E1.8 hybridoma cells, which we called ' backpacks '. MAbs were thereby introduced into the blood of animals with titres against ORF19 ranging from 1 : 1600 to 1 : 819 200. The mice were then infected in the same way as those immunized actively with the recombinant protein. Animals with titres of 1 : 102 400 and higher were also protected efficiently from MMTV(SW)-induced T-cell activation (Fig. 2 a) . The ' backpack ' immunization confirmed the protection previously reported (Acha and even improved it, providing complete inhibition. This strategy also made it possible to establish the titres of antibodies necessary to inhibit T-cell activation. The titres were compared to those necessary to obtain inhibition by active immunization : these titres were identical, although the protection was found to be less effective in mice with active immunization.
To ensure that T-cell activation by MMTV(SW) SAg was specifically inhibited by the anti-ORF19 MAbs, separate injections of MMTV(SW) and of MMTV(SNH) were made in the left and right footpads of each mouse carrying a ' backpack'. MMTV(SNH) is a recently described retrovirus which specifically activates the Vβ8 + CD4 + T cells (Luther et al., 1994) . Analysis of the percentage of Vβ6 + and Vβ8 + T cells in corresponding lymph nodes showed that inhibition was specific only in the case of MMTV(SW) (Fig. 2 b) .
The comparison in vivo between passive and active immunization showed that for similar antibody titres, their capacity to inhibit Vβ6-specific T-cell activation was very different. To understand the reasons for the difference, the affinity of antibodies obtained from the two immunizations for the C-terminal amino acids of MMTV(SW) SAg was analysed. Sera from mice carrying a ' backpack ' with 6E1.8 hybridoma and those from mice immunized with recombinant ORF19 protein were analysed using ELISA on the ORF19 epitope and on the last ten C-terminal amino acids of the MMTV(SW) SAg, hereafter referred to as ORF10 (Fig. 3 a) . These comparisons showed that mice immunized with the recombinant ORF19 protein were unable to recognize the last ten amino acids of the MMTV(SW) SAg.
Given that 6E1.8 used in vivo completely inhibited T-cell activation by MMTV(SW) SAg, we concluded that it was able FI Anti-superantigen vaccination Anti-superantigen vaccination Fig. 2. (a) Correlation between anti-ORF19 titres in the sera of mice immunized passively and analysis of protection against activation of Vβ6 + CD4 + T cells after MMTV(SW) infection. Sixweek-old BALB/c mice (Harlan Olac, Bicester, UK) were injected subcutaneously with 5i10 4 to 8i10 5 6E1.8 hybridoma cells to form antibody-secreting ' backpack ' tumours. Six days later, groups of mice with varying anti-ORF19 serum titres were selected by ELISA on the synthetic ORF19 peptide (KILYNMKYTHGGRVGFDPF) and infected by footpad injection with 2i10 6 to 2i10 7 MMTV(SW) viral particles. The percentage of Vβ6 + CD4 + T cells was determined by FACS analysis at day 5 after infection in the draining popliteal lymph node. Horizontal lines represent the arithmetic mean with standard deviation of the percentage of Vβ6 + CD4 + T cells in immunized but non-infected BALB/c control mice. Vertical lines represent the standard deviation of the arithmetic mean of two to three mice. ND, Not detectable. (b) Four-to six-week-old female BALB/c mice were injected subcutaneously with 4i10 6 6E1.8 hybridoma cells. Seven days later, groups of mice with varying anti-ORF19 titres were selected by ELISA on the synthetic ORF19 peptide and were infected either with MMTV(SW) in the left footpad (A) or MMTV(SHN) in the right footpad (B). The percentage of Vβ6 + or Vβ8 + CD4 + T cells was determined by FACS analysis in the respective draining lymph nodes at day 5 after infection. Vertical lines represent the arithmetic mean with standard deviation of the percentage of Vβ6 + or Vβ8 + CD4 + T cells in immunized but non-infected BALB/c control mice. Horizontal lines represent standard deviation of the arithmetic mean of two to three mice. Fig. 3. (a) Sera from BALB/c mice either injected subcutaneously with 6E1.8 hybridoma cells or immunized with recombinant ORF19 protein were analysed by ELISA on the synthetic peptide ORF19 (KILYNMKYTHGGRVGFDPF) or ORF10 (THGGRVGFDPF). (b) Identical concentrations of 6E1.8 MAbs were preincubated with an excess of 50 µg of different synthetic peptides as indicated, for 90 min at 37 mC in PBS containing 0n1 % Tween and 1 % skimmed milk. The preadsorbed antibodies were transferred in a microplate coated with synthetic ORF19 peptide and incubated at 37 mC for 1 h. After washing, antibodies still recognizing the native ORF19 peptide were detected with a biotinylated goat anti-IgG (Amersham) followed by streptavidin-HRP. Optical densities (OD 492 ) were measured using o-phenylenediamine as chromogen.
to recognize a particular sequence on the ORF19 peptide which is critical for the interaction of SAg with the TCR. In addition, this same sequence constitutes a neutralizing epitope whose immunodominant character we wanted to establish. In order to map the specificity of the antibody, three ORF peptides were produced with the following modifications : (i) a change in the last amino acid ; (ii) a deletion of the one before last ; and (iii) the deletion of the last three. The 6E1.8 antibody was preincubated separately with an excess of each of the modified peptides. When these pre-absorbed antibodies were analysed by ELISA on the native ORF19 peptide, it could be clearly shown that this antibody recognized the last two amino acids of the retroviral SAg (Fig. 3 b) . Therefore these two amino acids play a crucial role in the interaction of the MHC class II-MMTV(SW) SAg complex with the variable Vβ element of the TCR.
The present study confirms the immunoprotective role of an anti-SAg immunization through inhibition of retrovirus-FJ induced T-cell activation. This protection was established in passive immunization by subcutaneous injection of varying numbers of anti-SAg-secreting hybridoma cells. This strategy allowed us to establish the minimum titre of antibodies in the blood to provide neutralization of the SAg-induced activation. Similar and higher titres of anti-ORF19 antibodies obtained by active immunization with the recombinant protein also provided significant protection, but without offering complete inhibition. One reason could be the presence of residual nonneutralized SAg molecules : however, if that were so an increase in the antibody titre would improve protection, which proved not to be the case. It was therefore hypothesized that the presence of the histidine tag at the C-terminal site of the recombinant protein could induce a conformational change of the last amino acids of the SAg, which during immunization could prevent their immune recognition. This hypothesis was confirmed by the fact that the sera of mice immunized with the ORF19 recombinant protein did not recognize the last ten amino acids at the C terminus of the SAg.
Comparative analysis of the active and passive immunizations, as well as mapping of the MAb which provided the best protection, enabled us to establish the critical immunodominant role of the C-terminal dipeptide of the MMTV(SW) SAg.
This study also revealed that histidine tags attached to recombinant proteins and commonly used for purification can induce conformational changes which prevent proper recognition of some amino acids by the immune system. Therefore the histidine tag should be removed before immunization.
In conclusion, anti-SAg immunization provides effective protection against MMTV-induced T-cell activation. In this process, the C-terminal dipeptide of the SAg plays a critical role. A double immunization, combining an anti-gp52 envelope protein vaccination with the anti-SAg immunization, should provide maximum protection. If some viruses were to escape from neutralization of the virus-membrane interaction by anti-gp52 immunization, the expressed SAg on the surface of the B cells would still be prevented from interacting with the TCR receptor on the T cells by the anti-SAg antibodies.
